- Home
- WIT vs ONC Comparison
WIT vs ONC Comparison
Compare WIT & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIT | ONC |
|---|---|---|
| Founded | 1945 | 2010 |
| Country | India | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6B | 34.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WIT | ONC |
|---|---|---|
| Price | $2.93 | $310.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $369.50 |
| AVG Volume (30 Days) | ★ 7.8M | 272.0K |
| Earning Date | 01-15-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 14.66 | N/A |
| EPS | 0.14 | ★ 0.58 |
| Revenue | ★ $10,092,590,162.00 | $4,972,687,000.00 |
| Revenue This Year | $5.49 | $895.40 |
| Revenue Next Year | $5.47 | $22.04 |
| P/E Ratio | ★ $20.15 | $531.92 |
| Revenue Growth | 1.10 | ★ 50.43 |
| 52 Week Low | $2.55 | $172.67 |
| 52 Week High | $3.79 | $385.22 |
Technical Indicators
Market Signals| Indicator | WIT | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 55.94 |
| Support Level | $2.84 | $302.14 |
| Resistance Level | $2.96 | $310.88 |
| Average True Range (ATR) | 0.06 | 6.38 |
| MACD | -0.01 | 1.30 |
| Stochastic Oscillator | 32.79 | 100.00 |
Price Performance
Historical ComparisonAbout WIT Wipro Limited
Wipro is a multinational IT services provider based in Bengaluru, India. The company pivoted into the IT space in the 1980s and grew into one of the largest Indian IT consulting companies during the dot-com boom. Nowadays, Wipro leverages its offshore outsourcing model to derive a significant portion of its revenue from North America and Europe.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.